Say hello to MassDevice +3, a bite-sized view of the top three medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
A Dallas jury split its decision in a product liability lawsuit filed over Ethicon’s TVT-O pelvic mesh yesterday, awarding $1.2 million in compensatory damages to plaintiff Linda Batiste.
The jury found that the TVT-O product, a surgical mesh designed to treat pelvic organ prolapse and stress urinary incontinence in women, was defectively designed. But the jury declined to award punitive damages and ruled that the Johnson & Johnson subsidiary’s warnings about the risks of the TVT-O product were adequate. Read more
Bio-artificial liver maker Vital Therapies set the range for its initial public offering at $13 to $15 per share, below the $16 to $18 range it set last year before scuttling its 1st try at a U.S. IPO.
In March Vital Therapies filed updated registration statements signaling its intent to launch the IPO, wiping clean the pricing set in November 2013. Another filing today set the new price range for the 4.5-million-share offering at $58.5 million to $67.5 million. Read more
Medtronic’s In.Pact Admiral drug-eluting balloon, designed to treat peripheral artery disease, showed better target lesion revascularization rates after 6 months than rival C.R. Bard’s Lutonix DEB.
Results from the In.Pact SFA trial, announced April 5 at the Charing Cross international symposium in London, showed TLR rates of 1.4% for the In.Pact Admiral device, compared with 6.4% for the control arm. Bard’s Lutonix device and the control arm in its trial both showed TLR rates of about 3% at 6 months. Read more